Clinical Trials > Clinical
Trials of Interest > First Line, Low Toxic
Last update: 11/17/2009
> First
Line Low Toxic | First
Line Primary Therapy | Relapsed / refractory
| Addressing
other unmet needs
|
First Therapy (with minimal
expected toxicity)
Also
see Locating
First
Line
Therapies for Lymphoma
Follicular
Lymphoma and other low grade lymphomas / CLL
 | New:
Condition:
B-cell lymphomas, including CLL
|
|
|
| Enzastaurin (completed
enrollment)
Condition: Previously untreated
follicular NHL in
watchful waiting status
TOPIC SEARCH Mechanisms - PubMed
TOPIC SEARCH Outcome data - Medscape |
PubMed
TOPIC SEARCH Safety or Toxicity - PubMed
|
|
|
|
Biaxin-Based Antibiotic
Condition: Untreated advanced stage indolent Lymphoma
|
Addressing Other Unmet Needs:
TYPE: None-Interventional
Genomic and
Biobank | Outcomes and Toxicities | Quality
of Life | Screening Tests and Imaging
TOPIC SEARCH: Queries of ClinicalTrials.gov for Lymphoma
(none interventional types)
Genomic and Biobank
Studies
| Genome
Expression Study (highly recommended when it's time for a
biopsy)
Rationale: The observed variability in the clinical course of
follicular lymphoma, along with the diverse range of therapeutic
options available, makes it necessary for more refined
diagnostic stratification (such as by gene expression or
cytogenetic differences in the tumor cells).
Conditions: Lymphoma; Leukemia; Multiple Myeloma; Lymphoid
Malignancies
Locations:
Nebraska Medical Center in Omaha,
Southwest Oncology Group centers- see for centers http://www.swog.org/
the British Columbia Cancer Agency in Vancouver,
Canada;
the Norwegian Radium Hospital in Oslo, Norway;
the University of Würzburg in Würzburg,
Germany;
the University of Barcelona in Barcelona, Spain;
and
St. Bartholomew's Hospital in London, England.
Background: NCI investigators are working with researchers at
the University of Nebraska Medical Center in Omaha to define the
gene expression profiles of all types of human lymphoid
malignancies.
The project is supported by an international collaboration
... The LLMPP uses "Lymphochip" cDNA
(complementary DNA) microarrays, which are enriched in genes that
are expressed in and/or function in lymphocytes. Lymphochip
microarrays allow measurement of the RNA expression levels of the
represented genes. Gene expression profiles developed as a result
of this project may someday be used for disease classification
(diagnosis), prognosis, and therapy selection. Already, results
from the LLMPP indicate that these profiles can improve diagnostic
accuracy and provide prognostic information.
The LLMPP is initiating a multicenter clinical trial to evaluate a
lymphoma diagnostic chip, called LymphDX, which was designed by
the company Affymetrix in collaboration with NCI researchers using
LLMPP data. The study will demonstrate the feasibility of
disseminating the LymphDX microarray technology to all of the
participating sites and will also evaluate the diagnostic utility
of the LymphDX chip in a prospective study.
|
|
|
|
|
Outcomes and
Toxicities
Quality of Life
|
to identify chronic health conditions, psychological disease,
quality of life issues, and patient preferences for survivorship
care in patients who have survived aggressive lymphoma.
|
|
|
|
|
Screening Tests and
Imaging
Return to top
|
|
